Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/9/2025

Janusmed kön och genus

Janusmed kön och genus – Lorazepam Macure

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Lorazepam Testmiljö

Lorazepam

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Ativan, Ativan West-ward, Lorazepam, Lorazepam Baxter, Lorazepam Dorom......

Ativan, Ativan West-ward, Lorazepam, Lorazepam Baxter, Lorazepam Dorom, Lorazepam Intensol, Lorazepam Macure, Lorazepam Orifarm, Lorazepam Orion, Lorazepam Tablets, Lorazepam sublingual, Tavor, Tavor Pro Injectione 2 mg, Temesta, Temesta Expidet
ATC-koder

N05BA06

N05BA06
Substanser

lorazepam

lorazepam
Sammanfattning

I en mindre studie hade lorazepam en likvärdig effekt hos kvinnor och män avseende påverkan på beteendeeffekter och hjärnans metabolism. Det saknas evidens för kön- och genusskillnader vid andra användningsområden.

I en mindre studie hade lorazepam en likvärdig effekt hos kvinnor och män avseende påverkan på beteendeeffekter och hjärnans metabolism. Det saknas evidens för kön- och genusskillnader vid andra användningsområden.
Background

Women are two to three times more likely to suffer from an anxiety disorder [1]. Sex differences in symptomatology and comorbidity may be due to genetic, hormonal, neurodevelopmental, environmental, and neurobiological factors [2].

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of lorazepam have been found.

Effects
A study aimed to investigate the regional brain metabolic response to benzodiazepines in a cohort of men (n=16) and women (n=12). Positron emission tomography scans with fluorodeoxyglucose were conducted on two separate occasions: one before receiving a placebo and another before receiving lorazepam (30 μg/kg). The findings revealed a significant and consistent decrease in whole brain metabolism induced by lorazepam, with similar magnitudes and regional patterns of changes observed in both men and women. No significant differences were noted in any of the behavioral effects of lorazepam or changes in absolute metabolism between the two groups [5].

Adverse effects
No studies with a sex analysis r......

Visa hela bakgrundstexten

Women are two to three times more likely to suffer from an anxiety disorder [1]. Sex differences in symptomatology and comorbidity may be due to genetic, hormonal, neurodevelopmental, environmental, and neurobiological factors [2]. # Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of lorazepam have been found. # Effects A study aimed to investigate the regional brain metabolic response to benzodiazepines in a cohort of men (n=16) and women (n=12). Positron emission tomography scans with fluorodeoxyglucose were conducted on two separate occasions: one before receiving a placebo and another before receiving lorazepam (30 μg/kg). The findings revealed a significant and consistent decrease in whole brain metabolism induced by lorazepam, with similar magnitudes and regional patterns of changes observed in both men and women. No significant differences were noted in any of the behavioral effects of lorazepam or changes in absolute metabolism between the two groups [5]. # Adverse effects No studies with a sex analysis regarding adverse effects specific for lorazepam have been found. **Benzodiazepines in general** The frequency of adverse effects of benzodiazepines experienced in psychiatric outpatients has been evaluated in a questionnaire (60 men, 19 women). The most commonly reported adverse effects in both men and women were sleepiness, slowness and fatigue. The most evident sex difference was the higher prevalence of dizziness in women (31%) than men (6%) [3]. The risk of falls when using benzodiazepines was studied in a registry study (124 009 men, 197 413 women). Higher age and female sex were associated with a higher incidence of falls among benzodiazepine users and controls. A history of treatment of alcohol abuse was an important risk factor for falls in this group with an odds ratio of 10.7 in men and 4.3 in women [4]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande lorazepam (ATC-kod N05BA06) på recept i Sverige år 2022, totalt 2 347 kvinnor och 1 659 män. Det motsvarar 0,5 respektive 0,3 personer per tusen invånare. Andelen som hämtat ut var högst i åldersgruppen 75 år och äldre hos båda könen. I genomsnitt var läkemedel innehållande lorazepam 1,3 gånger vanligare hos kvinnor [6].
Referenser

Visa referenser

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].

  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.

  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.

  4. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25:273-8.

  5. Wang GJ, Volkow ND, Fowler JS, Hitzemann RJ, Pappas NR, Netusil N. Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Res. 1998;82(1):37-46.

  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.
  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.
  4. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25:273-8.
  5. Wang GJ, Volkow ND, Fowler JS, Hitzemann RJ, Pappas NR, Netusil N. Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Res. 1998;82(1):37-46.
  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]
Uppdaterat

Litteratursökningsdatum: 11/10/2023

Litteratursökningsdatum: 11/10/2023
Fasstexter

Visa fasstexter

A A
A A

Lorazepam Testmiljö

Lorazepam

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Ativan, Ativan West-ward, Lorazepam, Lorazepam Baxter, Lorazepam Dorom......

Ativan, Ativan West-ward, Lorazepam, Lorazepam Baxter, Lorazepam Dorom, Lorazepam Intensol, Lorazepam Macure, Lorazepam Orifarm, Lorazepam Orion, Lorazepam Tablets, Lorazepam sublingual, Tavor, Tavor Pro Injectione 2 mg, Temesta, Temesta Expidet
ATC-koder

N05BA06

N05BA06
Substanser

lorazepam

lorazepam
Sammanfattning

I en mindre studie hade lorazepam en likvärdig effekt hos kvinnor och män avseende påverkan på beteendeeffekter och hjärnans metabolism. Det saknas evidens för kön- och genusskillnader vid andra användningsområden.

I en mindre studie hade lorazepam en likvärdig effekt hos kvinnor och män avseende påverkan på beteendeeffekter och hjärnans metabolism. Det saknas evidens för kön- och genusskillnader vid andra användningsområden.
Background

Women are two to three times more likely to suffer from an anxiety disorder [1]. Sex differences in symptomatology and comorbidity may be due to genetic, hormonal, neurodevelopmental, environmental, and neurobiological factors [2].

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of lorazepam have been found.

Effects
A study aimed to investigate the regional brain metabolic response to benzodiazepines in a cohort of men (n=16) and women (n=12). Positron emission tomography scans with fluorodeoxyglucose were conducted on two separate occasions: one before receiving a placebo and another before receiving lorazepam (30 μg/kg). The findings revealed a significant and consistent decrease in whole brain metabolism induced by lorazepam, with similar magnitudes and regional patterns of changes observed in both men and women. No significant differences were noted in any of the behavioral effects of lorazepam or changes in absolute metabolism between the two groups [5].

Adverse effects
No studies with a sex analysis r......

Visa hela bakgrundstexten

Women are two to three times more likely to suffer from an anxiety disorder [1]. Sex differences in symptomatology and comorbidity may be due to genetic, hormonal, neurodevelopmental, environmental, and neurobiological factors [2]. # Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of lorazepam have been found. # Effects A study aimed to investigate the regional brain metabolic response to benzodiazepines in a cohort of men (n=16) and women (n=12). Positron emission tomography scans with fluorodeoxyglucose were conducted on two separate occasions: one before receiving a placebo and another before receiving lorazepam (30 μg/kg). The findings revealed a significant and consistent decrease in whole brain metabolism induced by lorazepam, with similar magnitudes and regional patterns of changes observed in both men and women. No significant differences were noted in any of the behavioral effects of lorazepam or changes in absolute metabolism between the two groups [5]. # Adverse effects No studies with a sex analysis regarding adverse effects specific for lorazepam have been found. **Benzodiazepines in general** The frequency of adverse effects of benzodiazepines experienced in psychiatric outpatients has been evaluated in a questionnaire (60 men, 19 women). The most commonly reported adverse effects in both men and women were sleepiness, slowness and fatigue. The most evident sex difference was the higher prevalence of dizziness in women (31%) than men (6%) [3]. The risk of falls when using benzodiazepines was studied in a registry study (124 009 men, 197 413 women). Higher age and female sex were associated with a higher incidence of falls among benzodiazepine users and controls. A history of treatment of alcohol abuse was an important risk factor for falls in this group with an odds ratio of 10.7 in men and 4.3 in women [4]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande lorazepam (ATC-kod N05BA06) på recept i Sverige år 2022, totalt 2 347 kvinnor och 1 659 män. Det motsvarar 0,5 respektive 0,3 personer per tusen invånare. Andelen som hämtat ut var högst i åldersgruppen 75 år och äldre hos båda könen. I genomsnitt var läkemedel innehållande lorazepam 1,3 gånger vanligare hos kvinnor [6].
Referenser

Visa referenser

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].

  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.

  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.

  4. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25:273-8.

  5. Wang GJ, Volkow ND, Fowler JS, Hitzemann RJ, Pappas NR, Netusil N. Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Res. 1998;82(1):37-46.

  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
  2. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.
  3. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.
  4. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25:273-8.
  5. Wang GJ, Volkow ND, Fowler JS, Hitzemann RJ, Pappas NR, Netusil N. Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Res. 1998;82(1):37-46.
  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]
Uppdaterat

Litteratursökningsdatum: 11/10/2023

Litteratursökningsdatum: 11/10/2023
Fasstexter

Visa fasstexter